BioRestorative Therapies, Inc. (BRTX)

Over the past six months (August 2025 to February 2026), BRTX's stock has trended down by 30.41%. In November 2025, BioRestorative Therapies reported its Third Quarter 2025 financial results, showing a decrease in revenues compared to Q3 2024 and an increased loss from operations year-over-year. In October 2025, the company strengthened its financial position by closing a registered direct offering priced above market and announced a notice of allowance for a Japanese patent for its ThermoStem® technology. In August 2025, BioRestorative Therapies reported its Second Quarter 2025 financial results, with a reported loss. In June 2025, the company reported compelling preliminary data for its FDA-Fast-Tracked BRTX-100. In May 2025, BioRestorative Therapies reported its First Quarter 2025 financial results, noting a decrease in revenues compared to the same period last year, an increased net loss, and announced a commercial agreement with Cartessa, while also receiving a Nasdaq non-compliance notice. In April 2025, the FDA cleared a Phase 2 BRTX-100 clinical study protocol amendment. In March 2025, BioRestorative Therapies reported its 2024 financial results, showing a reduced net loss compared to 2023 and the FDA also cleared an IND for a Phase 2 trial of BRTX-100 in chronic cervical discogenic pain. In February 2025, the company received FDA Fast Track Designation for its BRTX-100 chronic lumbar disc disease program and presented positive preliminary Phase 2 BRTX-100 clinical data.

There is no specific information available regarding demand seasonality for BioRestorative Therapies, Inc.'s products and services. Demand for its investigational products (BRTX-100 and ThermoStem®) would largely be driven by clinical trial progress and regulatory approvals rather than typical consumer seasonality. The BioCosmeceutical revenue stream has shown variations related to the specific timing of orders.

BioRestorative Therapies, Inc. (BRTX) is a clinical-stage biotechnology company focused on developing regenerative medicine products and therapies using adult stem cells, with a primary focus on cell and tissue protocols to address unmet medical needs. The company operates within the Healthcare sector, specifically in the Biotechnology industry. Its major product pipeline includes BRTX-100, an autologous cell therapy candidate in Phase 2 clinical trial for chronic lumbar disc disease; ThermoStem®, a cell-based therapy candidate utilizing brown adipose-derived stem cells for obesity and related metabolic disorders; and BioCosmeceuticals, a commercial platform exploring innovative applications in aesthetic medicine.

BioRestorative Therapies, Inc. is headquartered in Melville, New York, United States. While the company has secured international intellectual property, including a Japanese patent and an Israeli patent for its ThermoStem® technology, its primary research, manufacturing, and clinical development activities appear to be concentrated within the United States. The company has also confirmed that its BRTX-100 production and manufacturing are performed in the United States.

In the past year, BioRestorative Therapies has received a consensus "Sell" rating from analysts, with an average rating score of 1.00 based on one research report. Positive impacts on the company's reputation include positive preliminary data from the Phase 2 BRTX-100 clinical trial, FDA Fast Track Designation for BRTX-100, FDA clearance of clinical study protocols, and the allowance of key patents for its ThermoStem® technology in Japan and Israel. Negative impacts include a Nasdaq non-compliance notice and ongoing operating losses.

The ownership structure of BioRestorative Therapies (BRTX) stock is a mix of institutional, retail, and individual investors. Approximately 2.85% of the company's stock is owned by Institutional Investors, 4.27% by Insiders, and 92.88% by Public Companies and Individual Investors. Major institutional holders include Auctus Fund, LLC, Auctus Fund Management, LLC, Fleetco, Inc., Citadel Advisors LLC, The Vanguard Group, Inc., Geode Capital Management, LLC, Wealth Alliance, LLC, Sterne Agee Asset Management, Inc., Virtu Financial, Inc., and State Street Global Advisors, Inc. Significant individual insider owners include Westbury Bermuda Ltd, Trust Westbury, Antonio Joel San, Janet Montgomery, Dale Broadrick, John M. Desmarais, Joseph B. Swiader, Lance Alstodt (President, CEO, COB), Francisco Silva (VP of Research and Development), and Paul Jude Tonna.